The mortality and kidney outcome data are directionally positive for paridiprubart's ARDS and potential AKI indication, but the exploratory nature limits immediate regulatory impact. Monitor for any subsequent partnership, licensing, or financing announcements that could leverage these data. The stock may see a short-term positive reaction, but the lack of prespecified endpoints and need for confirmatory trials cap the catalyst's durability.
Price Chart
Executive Summary
Edesa Biotech reported exploratory data for paridiprubart in acute kidney injury (AKI) patients at the ERA Congress. In a combined AKI cohort of 101 patients, paridiprubart plus standard of care was associated with a 32% relative reduction in 28-day mortality (33% vs 49%, nominal p<0.005) and a 23% relative reduction in MAKE30 incidence (41% vs 53%, nominal p<0.005). These are exploratory, non-prespecified analyses, and confirmatory studies are required.
Key Facts
- Paridiprubart + SOC reduced adjusted 28-day mortality to 33% from 49% (32% relative reduction, nominal p<0.005) in a 101-patient AKI cohort.
- Paridiprubart + SOC reduced adjusted MAKE30 incidence to 41% from 53% (23% relative reduction, nominal p<0.005).
- Data are exploratory, not prespecified, and require confirmatory studies to establish efficacy in AKI.
- Safety profile was consistent with over 400 patients treated across studies; no significant differences in adverse events vs placebo.
- Findings were presented at the 63rd European Renal Association Congress on June 5, 2026.
Financial Impact
No financial figures provided; the filing reports clinical data only.
Risk Factors
- Data are exploratory and not prespecified; confirmatory studies are required before regulatory submission.
- Nominal p-values not adjusted for multiplicity; results may not replicate in a dedicated AKI trial.
- Edesa is a micro-cap ($63M market cap) with no approved products; clinical-stage biotech risk is high.
- No financial data or guidance provided in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-003931 |
| Document: 0001171843-26-003931-index-headers.html | 0001171843-26-003931 |
| Document: 0001171843-26-003931-index.html | 0001171843-26-003931 |
| Document: 0001171843-26-003931.txt | 0001171843-26-003931 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $2.92 | awaiting T+20 | — | $2.59 (−11.25%) |
Oct 15, 2026 12d ago | 8-K | $2.67 | awaiting T+20 | — | $2.59 (−3.00%) |
Oct 15, 2026 12d ago | Press Release | $2.67 | awaiting T+20 | — | $2.59 (−3.00%) |
Aug 19, 2026 9w ago | Press Release | $4.76 $4.14 | ▲ +13.03% | ▲ +13.03% | $2.59 (+45.59%) |
Jul 14, 2026 15w ago | EFFECT | $6.74 $5.52 | ▲ +18.10% | ▲ +20.59% | $2.59 (+61.57%) |
Jul 2, 2026 16w ago | S-3 | $7.50 $5.25 | ▼ −30.00% | ▼ −29.59% | $2.59 (−65.47%) |
Jun 5, 2026 20w ago | 8-K | $5.46 $7.21 | ▲ +32.05% | ▲ +30.19% | $2.59 (−52.56%) |
Jun 5, 2026 20w ago | Press Release | $5.46 $7.21 | ▲ +32.05% | ▲ +30.19% | $2.59 (−52.56%) |
May 29, 2026 21w ago | 8-K | $6.69 $8.13 | ▲ +21.52% | ▲ +22.82% | $2.59 (−61.29%) |
May 19, 2026 23w ago | Press Release | $11.95 $6.88 | ▼ −42.43% | ▼ −43.41% | $2.59 (−78.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers